BDWM
RNAM

Brewin Dolphin Wealth Management’s Avidity Biosciences RNAM Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-270
Closed -$6.65K – 336
2021
Q3 		$6.65K Hold
270
– – ﹤0.01% 304
2021
Q2 		$6.67K Hold
270
– – ﹤0.01% 305
2021
Q1 		$5.89K Buy
+270
New +$6.61K ﹤0.01% 295

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brewin Dolphin Wealth Management's RNAM Position: Q4 2021 in Review

Brewin Dolphin Wealth Management sold out of Avidity Biosciences (RNAM) in Q4 2021, closing a stake of 270 shares — an estimated $6.65K sold.

Brewin Dolphin Wealth Management first reported a position in RNAM in Q1 2021 and held it in 3 quarters. The position peaked at $6.67K in Q2 2021. 107 funds tracked by Wall St. Rank hold RNAM as of Q4 2021.

  • Brewin Dolphin Wealth Management reported no remaining Avidity Biosciences position as of Q4 2021 after selling out during the quarter.
  • Brewin Dolphin Wealth Management sold 270 Avidity Biosciences shares in Q4 2021, an estimated $6.65K.
  • Brewin Dolphin Wealth Management first reported a position in Avidity Biosciences in Q1 2021 and held it in 3 quarters.
  • Brewin Dolphin Wealth Management's Avidity Biosciences position peaked at $6.67K in Q2 2021.
  • 107 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2021.

Based on Brewin Dolphin Wealth Management's 13F filing for Q4 2021, filed 14 Nov 2022.